Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. Learn more at www.atalantatx.com.
Location: United States, Massachusetts, Boston
Total raised: $207M
Investors 1
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2025 | Series B | $97M | EQT |
| 13.01.2021 | Series A | $110M | F-Prime Ca... |
Mentions in press and media 11
| Date | Title | Description |
| 03.02.2025 | Atalanta Therapeutics: $97 Million (Series B) Raised For Advancing Two RNAi Therapies | Atalanta Therapeutics, a biotechnology company advancing RNA interference (RNAi) for the treatment of neurological diseases, announced the completion of a $97 million Series B funding to support Phase 1 clinical trials of the company’s inve... |
| 31.01.2025 | The Week’s Biggest Funding Rounds: Helion Energy Takes Top Spot In Another Slow Week | 5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2025 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 29.01.2025 | Atalanta Therapeutics: A New Dawn in Neurological Treatments | Atalanta Therapeutics is making waves in the biotech ocean. This Boston-based company has just secured $75 million in Series B funding, a lifeline for its ambitious plans to tackle neurological diseases. The funding round was led by EQT Lif... |
| 28.01.2025 | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease Tue, Jan 28, 2025 13:00 CET Report this content Atalanta Therapeutics is pioneering RNA int... |
| 28.01.2025 | Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies | Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and Huntington’s disease. The oversubscribed series B financing was co-led b... |
| 28.01.2025 | Atalanta Therapeutics Raises $75M in Series B Funding | Atalanta Therapeutics, a Boston, MA-based company developing RNA interference (RNAi) to treat neurological diseases, raised $75M in Series B funding. The round was led by EQT Life Sciences, co-led by Sanofi Ventures, with participation from... |
| 12.01.2021 | Daily funding roundup - January 11th, 2021 | Aulos Bioscience has raised $40M; Komodo Health landed $44M; EQRx secured $500M Hello Ralphie: Hello Ralphie is a New York-based veterinary telemedicine company. Hello Ralphie raised $1 million in seed funding from HearstLab and WPMC Fund. ... |
| 11.01.2021 | Atalanta Therapeutics Raises $110M in Series A Funding | Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atal... |
| 11.01.2021 | Atalanta Therapeutics Raises $110M in Series A Funding | Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atal... |
| 11.01.2021 | Atalanta Therapeutics Raises $110M in Series A Funding | Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atal... |
Show more